David Salvay
Ophthalmology · Newport Beach, CANPI 1700173655
Payments from drug & device makers
Across 112 payments — averaging $151.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$11K
- Johnson & Johnson Surgical Vision, Inc.$2K
- Alcon$836
- Bausch & Lomb, A Division Of Bausch Health US, LLC$515
- Rxsight Inc$476
- Glaukos Corporation$452
- plus $2K from 24 others
What the payments were for
- Travel & lodging$4427%
- Food & beverage$6,12493%
- Gifts$190%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 8 | $10,681 |
| Johnson & Johnson Surgical Vision, Inc. | 16 | $1,585 |
| Alcon | 21 | $836 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 5 | $515 |
| Rxsight Inc | 7 | $476 |
| Glaukos Corporation | 10 | $452 |
| Amgen | 5 | $428 |
| Tarsus Pharmaceuticals, Inc. | 6 | $296 |
| Lumenis BE Inc | 1 | $252 |
| Carl Zeiss Meditec, Inc. | 3 | $209 |
| NEW World Medical,inc. | 2 | $201 |
| Carl Zeiss Meditec USA, Inc. | 2 | $156 |
| Harrow Eye, LLC | 4 | $132 |
| Eyepoint US, Inc. | 1 | $124 |
| Beaver-visitec International, Inc. | 1 | $76 |
| Lensar, Inc. | 1 | $76 |
| Astellas Pharma US Inc | 1 | $64 |
| Sun Pharmaceutical Industries Inc. | 2 | $49 |
| Bausch & Lomb Americas Inc. | 2 | $46 |
| Akorn, Inc. | 2 | $36 |
| Sight Sciences, Inc. | 2 | $35 |
| Oyster Point Pharma, Inc. | 1 | $34 |
| Mallinckrodt Hospital Products Inc. | 2 | $34 |
| Topcon Healthcare, Inc. | 1 | $24 |
| Kala Pharmaceuticals, Inc. | 1 | $22 |
| Carl Zeiss Meditec AG | 1 | $19 |
| Thea Pharma Inc. | 1 | $19 |
| Optos, Inc. | 1 | $19 |
| Eyevance Pharmaceuticals LLC | 1 | $18 |
| Ocular Therapeutix, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Tecnis 1-piece IOL$762
- Tecnis 3-piece IOL$762
- Tecnis Symphony IOL$762
- Tecnis Symphony Toric IOL$762
- TEPEZZA$381
- RXSIGHT CONTACT LENS$264
- RXSIGHT INJECTOR CARTRIDGE$264
- RXSIGHT INJECTOR HANDPIECE$264
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$264
- LIGHT ADJUSTABLE LENS (LAL)$264
- optilight$252
- Tecnis IOL$247
- XEN GLAUCOMA TREATMENT SYSTEM$247
- TRYPTYR$146
- AcrySof IQ PanOptix UV IOL$144
- Clareon$141
- ARGOS$141
- Hydrus Microstent$141
- iStent inject Trabecular Micro-Bypass Stent System$126
- LIGHT ADJUSTABLE LENS (LAL) AND LIGHT DELIVERY DEVICE (LDD)$125
How this compares
$16,934 in reported general payments places this provider in the 85th percentile of 2,513 ophthalmology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 47 | $38,466 |
| LumiganBimatoprost | 33 | $23,046 |
| CombiganBrimonidine Tartrate/Timolol | 21 | $6,729 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 312 | $6,136 |
| Alphagan PBrimonidine Tartrate | 18 | $6,063 |
| Latanoprost | 433 | $5,665 |
| Brimonidine Tartrate | 228 | $5,631 |
| Travoprost | 37 | $4,245 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 12 | $3,506 |
| Prednisolone Acetate | 87 | $2,807 |
| Timolol Maleate | 235 | $2,233 |
| Fluorometholone | 33 | $2,175 |
| ValacyclovirValacyclovir Hcl | 19 | $2,036 |
| Brinzolamide | 12 | $1,860 |
| Loteprednol Etabonate | 13 | $1,556 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan, Alphagan P | $10,681 | $74,304119 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $515 | $1,55613 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,513 ophthalmology providers in California.
Other ophthalmology in Newport Beach
- David WirtaNewport Beach$18.4M
- Sheri RowenNewport Beach$1.8M
- Ehsan SadriNewport Beach$1.3M
- Nisha AcharyaSan Francisco$33M
- Michael IpPasadena$10.2M
- Raymond DouglasBeverly Hills$9.7M
- Sherif El HaraziGlendale$9.2M
- Daniel SchwartzSan Francisco$8M
- Nikolas Londonla Jolla$6.1M
- Michael BerlinWest Hollywood$5.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.